Pamela A. Davol

Anti-CD3 × Anti-Epidermal Growth Factor Receptor (EGFR) Bispecific Antibody Redirects T-Cell Cytolytic Activity to EGFR-Positive Cancers <i>In vitro</i> and in an Animal Model

Ursula Reusch, Magesh Sundaram, Pamela A. Davol et al. · Clinical Cancer Research · 2006 · 106 citations · Full text

Medicine, Oncology, Pharmacology +17

Antibody Targeting of Stem Cells to Infarcted Myocardium

Randall J. Lee, Qizhi Fang, Pamela A. Davol et al. · Stem Cells · 2006 · 84 citations · Full text

Pharmacy, Cardiology, Cell Biology +17

Human T Cells Armed with Her2/neu Bispecific Antibodies Divide, Are Cytotoxic, and Secrete Cytokines with Repeated Stimulation

Ryan C. Grabert, Leslie P. Cousens, Janelle A. Smith et al. · Clinical Cancer Research · 2006 · 79 citations · Full text

Life Sciences, Cancer Biology, Immunology +17

Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer.

Pamela A. Davol, Robert Bagdasaryan, Gerald J. Elfenbein et al. · PubMed · 2003 · 72 citations

Medicine, Molecular Biology, Oncology +17

T cells armed with anti-CD3 × anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro

Jonathan M. Gall, Pamela A. Davol, Ryan C. Grabert et al. · Experimental Hematology · 2005 · 62 citations · Full text

Life Sciences, Hematology, Immunology +16